Background- Infectious hyphae can invade the blood vessels, leading to necrosis of the structures involved in rhino-orbital-cerebral mucormycosis. Large cases have been recorded from India, proving that this clinical entity is regionally variable. According to the disease' s stage, the affected individuals experience different levels of clinical suffering. Treatment for rhino-orbital- cerebral mucor-mycosis requires a multidisciplinary strategy. This study compared the effectiveness of amphotericin and amphotericin with posaconazole in treating rhinoorbitocerebral mucormycosis caused by Covid 19 infection. Methodology- A total of 36 subjects were included in the current investigation who were presented with Rhinoorbitocerebral mucormycosis. This was a double-blinded randomized controlled trial study conducted between May 2021 to August 2021. Patients have then divided into two groups: Group A, received Amphotericin alone in postoperative care. Group B, received Amphotericin along with posaconazole in postoperative care. Results- Among 36 patients, majority of the patients 14 (38.9%) belonged to the age group of 50 – 60yrs and males were showing gender preponderance 27 (75%). Majority of the patients (66.7%) had not used Amphoterecin alone, not used amphoterecin and posoconazole. Among those patients who had used 20-30 vials of Amphoterecin alone, majority of the patients (63.6%) had used Amphoterecin with Posaconazole drug. This is not found to be statistically Significant (p=0.658). Conclusion- During the COVID-19 pandemic, rhinoorbitocerebral nmucormycosis was one of the most prevalent and severe fungal diseases seen. The best way to increase survival rates in these situations is through early detection, appropriate antifungal dosage, and prompt action. As compared to amphotericin alone, posaconazole plus amphotericin resulted in better outcomes. The study reveals that even though it was not statistically significant, it was clinically important.